Peter Rands News Today

Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the "Company") between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proceeds of...

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR ...

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused...

Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion...

LONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused...

Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PT...

Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PTLONDON, March 09, 2022 -- Small Pharma Inc. , a neuroscience company focused on psychedelic-assisted therapies for mental... | March 9, 2022

Peter Rands, Chief Executive Officer, Small Pharma Inc. ("Small Pharma" or "the Company") (TSXV: DMT), and his team joined Dani Lipkin, Director, Global Business Development TMX Group, to celebrate the Company's new listing on TSX Venture Exchange and open the market.

Small Pharma on conducting world’s first clinical trials for psychedelic DMT and listing in Canada Small Pharmas (CVE:DMT) Peter Rands joins Proactive to introduce his company after launching on Toronto’s TSX Venture Exchange, raising C$58mln to develop medicines based on N,N-Dimethyltryptamine (DMT) to treat depression. The firm is committed to helping accelerate the development of effective therapeutic treatments for mental health disorders. The company is currently conducting the world�...